Skip to content

Oncology (Pediatrics)

Individualized/Modified Chemotherapy (Dose Adjustment or Delay)

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. (opens new window)

Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH

Source‎: N Engl J Med 1998;338(8):499-505.

Indexed‎: PubMed 9468466

DOI‎: 10.1056/NEJM199802193380803

https://www.ncbi.nlm.nih.gov/pubmed/9468466 (opens new window)

Childhood cancer and the Jehovah's Witness faith. (opens new window)

Frankel LS, Damme CJ, Eys JV.

Source‎: Pediatrics 1977;60(6):916-21.

Indexed‎: PubMed 600607

https://www.ncbi.nlm.nih.gov/pubmed/600607 (opens new window)

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. (opens new window)

Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung NK

Source‎: J Clin Oncol 2004;22(24):4888-92.

Indexed‎: PubMed 15611504

DOI‎: 10.1200/JCO.2004.02.101

https://www.ncbi.nlm.nih.gov/pubmed/15611504 (opens new window)

Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group AAML1331 Trial. (opens new window)

Kutny MA, Alonzo TA, Abla O, Rajpurkar M, Gerbing RB, Wang YC, Hirsch BA, Raimondi S, Kahwash S, Hardy KK, Hardy S, Meshinchi S, Gamis AS, Kolb EA, Feusner JH, Gregory J Jr

Source‎: JAMA Oncol 2022;8(1):79-87. 

Indexed‎: PubMed 34762093

DOI‎: 10.1001/jamaoncol.2021.5206

https://pubmed.ncbi.nlm.nih.gov/34762093/ (opens new window)

Acute leukemia in Jehovah's Witnesses: a challenge for hematologists. (opens new window)

Mazza P, Palazzo G, Amurri B, Cervellera M, Rizzo C, Maggi A

Source‎: Haematologica 2000;85(11):1221-2.

Indexed‎: PubMed 11064477

https://www.ncbi.nlm.nih.gov/pubmed/11064477 (opens new window)

Autologous and allogeneic stem cell transplant in Jehovah's Witnesses: a single-center experience on 22 patients. (opens new window)

Mazza P, Palazzo G, Minoia C, Amurri B, Pisapia G

Source‎: Bone Marrow Transplant 2016;51(7):1002-3.

Indexed‎: PubMed 26950381

DOI‎: 10.1038/bmt.2016.29

https://www.ncbi.nlm.nih.gov/pubmed/26950381 (opens new window)

Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. (opens new window)

Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L, Pricolo G.

Source‎: Bone Marrow Transplant 2003;32(4):433-6.

Indexed‎: PubMed 12900781

DOI‎: 10.1038/sj.bmt.1704179

https://www.ncbi.nlm.nih.gov/pubmed/12900781 (opens new window)

Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. (opens new window)

Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarín-Arzaga LD, Manzano C.

Source‎: Bone Marrow Transplant 2005;36(8):715-20.

Indexed‎: PubMed 16113672

DOI‎: 10.1038/sj.bmt.1705126

https://www.ncbi.nlm.nih.gov/pubmed/16113672 (opens new window)

Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia. (opens new window)

Zwaan CM, Kaspers GJ

Source‎: Br J Haematol 2004;127(3):264-79.

Indexed‎: PubMed 15491285

DOI‎: 10.1111/j.1365-2141.2004.05167.x

https://www.ncbi.nlm.nih.gov/pubmed/15491285 (opens new window)